You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mesenchymal-Epithelial Transition exon 14 Skipping Mutation Positive Advanced Non-Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

Recruiting
  • Non-Small Cell Lung Carcinoma
  • Capmatinib 150 mg
  • Capmatinib 200 mg
  • Guwahati, Assam, India
  • +7 more
Dec 19, 2022

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer
  • San Francisco, California
    University of California San Francisco
Aug 15, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

    Completed
    • Metastatic Non-Small Cell Lung Cancer
    • East Hanover, New Jersey
      18 Novartis Investigative Sites in the US
    Dec 29, 2022

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Fairfax, Virginia
      NEXT Virginia
    Sep 18, 2023

    EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

    Recruiting
    • EGFR Exon 20 Mutation
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 12, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

    Recruiting
    • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 21, 2023

    Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

    Recruiting
    • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 25, 2023

    Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

    Not yet recruiting
    • Advanced Cancer
    • Non Small Cell Lung Cancer
    • (no location specified)
    Mar 28, 2023

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Mar 24, 2023

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +3 more
    • New Haven, Connecticut
    • +4 more
    Jan 27, 2023

    NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

    Completed
    • Carcinoma, Non-Small-Cell Lung
    • Duarte, California
    • +8 more
    Jan 31, 2023

    EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among

    Recruiting
    • Lung Cancer
    • Kuala Lumpur, Malaysia
    • +2 more
    Nov 21, 2022

    Non-squamous NSCLC, Epithelial Ovarian Cancer Trial (AMG 794)

    Not yet recruiting
    • Non-squamous Non-small Cell Lung Cancer
    • Epithelial Ovarian Cancer
    • AMG 794
    • Orange, California
      University of California at Irvine
    Jan 25, 2023

    Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

    Not yet recruiting
    • Lung Cancer
    • +4 more
    • (no location specified)
    Sep 15, 2023

    NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

    Recruiting
    • NSCLC
    • Furmonertinib 160mg
    • Furmonertinib 240mg
    • Shanghai, China
      Shanghai Chest hospital
    Jan 16, 2023

    Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma Trial (Capmatinib)

    Available
    • Carcinoma, Non-Small Cell Lung
    • +3 more
    • (no location specified)
    Aug 31, 2021